IL10 polymorphisms associated with Behçet's disease in Chinese Han
Ziyan Wu1, Wenjie Zheng1, Juanjuan Xu1
1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.
Objective:
IL-10 is a potent anti-inflammatory cytokine that plays important roles in the pathogenesis of Behçet's disease (BD). Two genome-wide association studies have identified IL10 as a potential risk factor for BD. Here, we investigated the association between IL10 polymorphisms and BD in Chinese Han.
Methods:
407 BD patients and 679 healthy controls were enrolled, and genotyped by Sequenom MassArray system (Sequenom iPLEX assay, San Diego, CA).
Results:
The frequency of risk allele of rs1800871 was notably higher in BD patients than in controls (71.9% vs. 66.2%, OR: 1.30, 95%CI: 1.08-1.58, pc=0.024). Similarly, rs1518111, which showed strong linkage disequilibrium (r(2)=1) with allele rs1800871, was also associated with BD (pc=0.026). Rs3021094 was in association with BD in a dominant model (pc=0.035), and the haplotype (GACC) formed by rs1518111, rs3021094, rs3790622, and rs1800871 was associated with BD (pc=0.023). Results obtained from meta-analysis combined with our data showed that rs1800871 and rs1518111 were associated with BD.
Conclusion:
IL10 may be the susceptibility gene for BD in Chinese Han population.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
12:40Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
Published on: April 6, 2015
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Inflammatory Bowel Disease III: Crohn's Disease
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
